Abstract
Akathisia is a frequent and common adverse effect of treatment with antipsychotic (neuroleptic) drugs. This syndrome consists of subjective (feeling of inner restlessness and the urge to move) as well as objective components (rocking while standing or sitting, lifting feet as if marching on the spot and crossing and uncrossing the legs while sitting). Antipsychotic-induced akathisia can be classified according to the time of onset in the course of antipsychotic treatment (acute, tardive, withdrawal and chronic akathisia). Reported prevalence rates vary widely between 5 and 36.8%. Numerous risk factors for acute akathisia have been described and the exact pathophysiology of akathisia is still unknown.
Since akathisia is a drug-induced adverse effect, optimal management involves its prevention rather than treatment. Standardised titration and the use of novel antipsychotics are successful measures of prevention.
This paper reviews different forms of therapeutic approaches for the treatment of akathisia. Based on the available literature, propranolol or other lipophilic β-blockers seem to be the most consistently effective treatment for acute akathisia. There is nothing in the literature to guide a clinician when treatment with β-blockers fails. Addition of benzodiazepines would appear to be a sensible next choice, especially if subjective distress persists. If all of these drugs are unsuccessful, amantadine or clonidine can be tried. Other agents that have been investigated include ritanserin, piracetam, valproic acid (sodium valproate) and tricyclic antidepressants. Evidence on the treatment of tardive akathisia is unsatisfactory.
Similar content being viewed by others
References
Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systemic investigation of acute psychiatric inpatient admission. Br J Psychiatry 1983; 143 139–50
Fleischhacker WW, Miller CH, Schett P, et al. The Hillside Akathisia Scale: a reliability comparison of the English and German versions. Psychopharmacology (Berl) 1991; 105: 141–4
Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42: 874–8
Sachdev P. The epidemiology of drug induced akathisia: part 1: acute akathisia. Schizophr Bull 1995; 21: 431–49
Munetz MR, Cornes CL. Distinguishing akathisia and tardive dyskinesia. J Clin Psychopharmacol 1983; 3: 343–50
Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry 1985; 42: 166–9
Sachdev P. Akathisia and restlessness. Melbourne: Press Syndicate of the University of Cambridge, 1995
Sachdev P. Research diagnostic criteria for drug induced akathisia: conceptualization, rationale and proposal. Psychopharmacology 1994; 114: 181–6
National Institute of Mental Health, and Psychopharmacology survey center collaborative study group. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 161–246
Ayd FJ. High potency neuroleptics and akathisia. J Clin Psychopharmacol 1984; 4: 227–30
van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984; 41: 1036–9
Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admission. Br J Psychiatry 1993; 143: 139–50
Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug induced akathisia. Arch Gen Psychiatry 1994; 51: 963–74
Miller CH, Hummer M, Oberbauer H, et al. Dose escalation influenced the risk of neuroleptic induced akathisia. Eur Neuropsychopharmacol 1997; 7: 51–7
Saffermann AZ, Lieberman JA, Pollack S, et al. Akathisia and clozapine treatment. J Clin Psychopharmacol 1993; 13: 286–7
Kurz M, Hummer M, Kemmler G, et al. Long term pharmacokinetics of clozapine. Br J Psychiatry 1998; 173: 341–4
Cohen BM, Keck PE, Satlin A. Prevalence and severity of akathisia in patients on clozapine. Br J Psychiatry 1991; 29: 1215–9
Miller CH, Mohr F, Umbricht D, et al. The prevalence of acute extrapyramidal sings and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59: 2, 69–75
Ayd FJ. A survey of drug induced extrapyramidal reactions. J Am Med Assoc 1961; 175: 1054–60
Marsden CD, Jenner P. The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med 1980; 10: 55–72
Goldstein J, Litwin L, Malick J. Ritanserin increases spontaneous activity of A9 and A10 dopamine neurons [abstract]. Fed Proc 1987; 46: 966
Wiesel FA. Effects of high dose propranolol treatment on dopamine and norepinephrine metabolism in regions of rat brain. Neurosci Lett 1976; 2: 35–8
Bersani G, Grispini A, Marini S, et al. Neuroleptic induced extrapyramidal side effects: clinical perspectives with ritanserin, a new selective 5HT2 receptor blocking agent. Curr Ther Res 1986; 40: 492–9
Bersani G, Grispini A, Marini S, et al. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13: 500–6
Miller CH, Fleischhacker WW, Ehrmann H, et al. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373–6
Lipinski Jr JF, Mallya G, Zimmermann P, et al. Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychopharmacol 1989; 50: 339–42
Sachdev P. The Identification and management of drug induced akathisia. CNS Drugs 1995; 4: 28–46
Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Arch Gen Psychiatry 1988; 45: 79–91
Lipinski Jr JF, Zubenko GS, Barreira PJ, et al. Propanolol in the treatment of neuroleptic induced akathisia. Lancet 1983; I: 685–6
Lipinski Jr JF, Zubenko GS, Cohen BM, et al. Propanolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1984; 141: 412–5
Adler LA, Angrist B, Peselow E, et al. Acontrolled assessment of propanolol in the treatment of neuroleptic induced akathisia. Br J Psychiatry 1986; 149: 42–5
Adler LA, Angrist B, Peselow E, et al. Clonidine in neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 235–6
Adler LA, Angrist B, Peselow E. Efficacy of propanolol in neuroleptic induced akathisia. J Clin Psychopharmacol 1985; 5: 164–6
Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic induced akathisia. J Clin Psychopharmacol 1990; 10: 12–21
Deron C, Wlink W, Buylaet W, et al. Which beta blocker for the restless legs? Lancet 1984; I: 875
Reiter S, Adler LA, Erle S, et al. Neuroleptic induced akathisia treated with pindolol. Am J Psychiatry 1987; 144: 1241–2
Adler LA, Reiter S, Angrist B. Pindolol and propanolol in neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 1241–2
Zubenko GS, Cohen BM, Lipinski Jr JF, et al. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253–9
Dumon JP, Catteau J, Lavin F. Randomized, double blind, crossover, placebo controlled comparison of propanolol and betaxolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1992; 149: 647–50
Dupuis B, Catteau J, Dumon JP. Comparison of propanolol, sotalol and betaxolol in the treatment of neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 802–5
Wells BG, Cold JA, Marken PA. A placebo controlled trial of nandolol in the treatment of neuroleptic induced akathisia. J Clin Psychiatry 1991; 52: 255–60
Reiter S, Adler LA, Erle S. Atenolol and propanolol in neuroleptic induced akathisia. J Clin Psychopharmacol 1987; 7: 279–80
Ekbom A. Irritable legs. Acta Med Scand 1944; 118: 197–8
Morgan LK. Restless limbs: a commonly overlooked symptom controlled by valium. Med J Aust 1967; 589-94
Bartels M, Heide K, Mann K. Treatment of akathisia with lorazepam: an open trial. Pharmacopsychiatry 1987; 20: 51–3
Kutcher S, Williamson P, MacKenzie S, et al. Successful clonazepam treatment of neuroleptic induced akathisia in older adolescents and young adults: a double blind study. J Clin Psychopharmacol 1989; 9: 403–6
Kutcher S, MacKenzie S, Galarraga J, et al. Clonazepam treatment of adolescents with neuroleptic induced akathisia. Am J Psychiatry 1987; 144: 823–4
Donlon PT. The therapeutic use of diazepam for akathisia. Psychosomatics 1973; 14: 222–5
Gagrat D, Hamilton J, Belmaker R. Intravenous diazepam in the treatment of neuroleptic induced dystonia or akathisia. Am J Psychiatry 1978; 135: 1232–3
van Putten T, Mutalipassi LR, Malkin MD. Phenothiazine induced decompensation. Arch Gen Psychiatry 1974; 30: 102–5
Friis T, Christensen T, Gerlach J. Sodium valproate and biperiden in neuroleptic induced akathisia, parkinsonism and hyperkinesia: a double blind cross over study with placebo. Acta Psychiatr Scand 1982; 67: 178–87
Di Mascio A, Bernardo DL, Greenblatt D, et al. A controlled trial of amantadine in drug induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599–602
Sachdev P, Loneragan C. Intravenous benztropine and propanolol challenges in acute neuroleptic induced akathisia. Clin Neuropharmacol 1993; 16: 324–31
Adler LA, Peselow E, Rosenthal M, et al. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 1993; 29: 283–6
Tune L, Cole JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology 1981; 79: 9–15
Langer SZ. Presynaptic receptors and their role in the regulation of transmitter release. Br J Pharmacol 1977; 60: 481–97
Adler LA, Reiter S, Corwin J, et al. Differential effects of propanolol and benztropine in patients with neuroleptic induced akathisia. Psychopharmacol Bull 1987; 23: 519–21
Gelenberg AJ. Amantadine in the treatment of benztropine refractory extrapyramidal disorders induced by antipsychotic drugs. Curr Ther Res 1978; 22, 375–80
Zubenko GS, Barreira PJ, Lipinski Jr JF, Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol 1984; 4: 218–20
Fleischhacker WW, Bergman KJ, Pestreich LK, et al. The Hillside Akathisia Scale, a new rating instrument for neuroleptic induced akathisia. Psychopharmacol Bull 1989; 25: 222–6
Verbnyi Y, Derzhiruk LP, Moglilevskii AY. Piracetam induced changes in the functional activity of neurons as a possible mechanism for the effects of nootropic agents. Neurosci Behav Physiol 1996; 26(6): 507–15
Kabes J, Sikora J, Pisvejc J, et al. Effects of piracetam on extrapyramidal side effects induced by neuroleptic drugs. Int Pharmacopsychiatr 1982; 17: 185–92
Danel T, Servant D, Goudemand M. Amitriptyline in the treatment of neuroleptic induced akathisia. Biol Psychiatry 1988; 23: 186–8
Burke RE, Kang UJ, Jankovic J. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157–75
Levin H, Chengappa KN, Kambhampti RK, et al. Should chronic treatment refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992; 53: 248–51
Fleischhacker WW, Hummer M. Drug treatment of schizophrenia in the 1990s: achievements and future possibilities in optimising outcomes. Drugs 1997; 53(6): 915–29
Stein MB, Pohlman ER. Tardive akathisia associated with low dose haloperidole use. J Clin Psychopharmacol 1987; 7: 200–3
Yassa R, Iskandar H, Nastase C. Propanolol in the treatment of tardive akathisia: a report of two cases. J Clin Psychopharmacol 1988; 43: 544–7
Weiner WJ, Luby ED. Persistent akathisia following neuroleptic withdrawal. Ann Neurol 1983; 13: 466–7
Yassa R, Bloom D. Lorazepam and anticholinergics in tardive akathisia. Biol Psychiatry 1990; 27: 463–7
Sachdev P, Chee KY. Pharmacological characterization of tardive akathisia. Biol Psychiatry 1990; 28: 809–18
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, C.H., Fleischhacker, W.W. Managing Antipsychotic-Induced Acute and Chronic Akathisia. Drug-Safety 22, 73–81 (2000). https://doi.org/10.2165/00002018-200022010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200022010-00006